&lt;i&gt;&lt;b&gt;Bifidobacterium&lt;/b&gt;&lt;/i&gt;&lt;b&gt; species lower serum glucose, increase expressions of insulin signaling proteins, and improve adipokine profile in diabetic &lt;/b&gt;&lt;b&gt;mice &lt;/b&gt;

Le, Thi Kim Chung; Hosaka, Toshio; Nguyen, Thanh Trung; Kassu, Afework; Dang, Thi Oanh; Tran, Hong Ba; Pham, Tran Phuong; Tran, Quang Binh; Pham, Xuan Da

doi:10.2220/biomedres.36.63

Cited by 78 publications

(45 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bifidobacterium species also induce the adiponectin gene expression and decrease in macrophage chemoattractant protein-1 (MCP-1) and IL-6 expression. In conclusion, the results from this work suggest that Bifidobacterium species may be the promising bacteria for treat diabetes [25].…”

Section: Probiotics In Animal Models Of Autoimmune Diabetesmentioning

confidence: 59%

Probiotic Applications in Autoimmune Diseases

Oliveira¹

2018

Probiotics - Current Knowledge and Future Prospects

View full text Add to dashboard Cite

Evidences from animal models and humans have implied the involvement of alterations in the gut microbiota in development of some autoimmune diseases. Dysbiosis observed in autoimmune diseases is associated with decreased bacteria function and diversity, impaired epithelial barrier function, inflammation, and decreased regulatory T cells in the gut mucosa. Studies suggest that probiotics influence systemic immune responses, ensure the homeostasis of the healthy microbiota in the intestinal mucosa, and could, therefore, be used as adjuvant therapy to treat immune-mediated diseases. The mechanisms proposed to achieve this include mucus secretion; antimicrobial peptide production; the maintenance of the function of the gastrointestinal-epithelial barrier, ensuring adequate interactions between the gut microbiota and the mucosal immune cells; and, finally, helping the activation of host immune system in response to pathobionts. Here, we described several reports concerning probiotic applications in several animal models of autoimmune diseases and data of the main clinical trials concerning the applicability of probiotics in type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.

show abstract

Section: Probiotics In Animal Models Of Autoimmune Diabetesmentioning

confidence: 59%

Probiotic Applications in Autoimmune Diseases

Oliveira¹

2018

Probiotics - Current Knowledge and Future Prospects

View full text Add to dashboard Cite

show abstract

“…and Lactobacillus , in addition to glucose intolerance ( 58 ). Moreover, in experimental models of T2D, the administration of bacteria of the Bifidobacterium genus improves glucose tolerance and confers a protective role in the development of T2D ( 59 , 60 ). Similarly, the administration of Bacteroides acidifaciens decreases insulin resistance and even prevents obesity ( 61 ).…”

Section: Gut Dysbiosis In Inflammatory Diseasesmentioning

confidence: 99%

NLR and Intestinal Dysbiosis-Associated Inflammatory Illness: Drivers or Dampers?

et al. 2020

View full text Add to dashboard Cite

The intestinal microbiome maintains a close relationship with the host immunity. This connection fosters a health state by direct and indirect mechanisms. Direct influences occur mainly through the production of short-chain fatty acids (SCFAs), gastrointestinal hormones and precursors of bioactive molecules. Indirect mechanisms comprise the crosstalk between bacterial products and the host's innate immune system. Conversely, intestinal dysbiosis is a condition found in a large number of chronic intestinal inflammatory diseases, such as ulcerative colitis and Crohn's disease, as well as in diseases associated with low-grade inflammation, such as obesity, type 1 and 2 diabetes mellitus and cardiovascular diseases. NOD-Like receptors (NLRs) are cytoplasmic receptors expressed by adaptive and innate immune cells that form a multiprotein complex, termed the inflammasome, responsible for the release of mature interleukin (IL)-1β and IL-18. NLRs are also involved in the recognition of bacterial components and production of antimicrobial molecules that shape the gut microbiota and maintain the intestinal homeostasis. Recent novel findings show that NLRs may act as positive or negative regulators of inflammation by modulating NF-κB activation. This mini-review presents current and updated evidence on the interplay between NLRs and gut microbiota and their dual role, contributing to progression or conferring protection, in diabetes and other inflammatory diseases.

show abstract

“…In summary, Bifidobacterium spp. can be considered as a promising bacteria for treating T1D ( 120 ). Since it has been known that SCFAs are able to ameliorate intestinal epithelial barrier integrity, which is responsible partly for protection against T1D ( 80 ), many scientists are interested to study the effect of some probiotics that modulate the gut microbiota leading to the increase of the production of this metabolite.…”

Section: Future Of T1d Management By Microbiome Therapymentioning

confidence: 99%

Epigenetic Effects of Gut Metabolites: Exploring the Path of Dietary Prevention of Type 1 Diabetes

et al. 2020

View full text Add to dashboard Cite

Type 1 diabetes (T1D) has increased over the past half century and has now become the second most frequent autoimmune disease in childhood and one of major public health concern worldwide. Evidence suggests that modern lifestyles and rapid environmental changes are driving factors that underlie this increase. The integration of these two factors brings about changes in food intake. This, in turn, alters epigenetic regulations of the genome and intestinal microbiota composition, which may ultimately play a role in pathogenesis of T1D. Recent evidence shows that dysbiosis of the gut microbiota is closely associated with T1D and that a dietary intervention can influence epigenetic changes associated with this disease and may modify gene expression patterns through epigenetic mechanisms. In this review focus on how a diet can shape the gut microbiome, its effect on the epigenome in T1D, and the future of T1D management by microbiome therapy.

show abstract

<i><b>Bifidobacterium</b></i><b> species lower serum glucose, increase expressions of insulin signaling proteins, and improve adipokine profile in diabetic </b><b>mice </b>

Cited by 78 publications

References 33 publications

Probiotic Applications in Autoimmune Diseases

Probiotic Applications in Autoimmune Diseases

NLR and Intestinal Dysbiosis-Associated Inflammatory Illness: Drivers or Dampers?

Epigenetic Effects of Gut Metabolites: Exploring the Path of Dietary Prevention of Type 1 Diabetes

Contact Info

Product

Resources

About